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Abstract
Background: in HIv-infected patients with Hcv-relat-
ed chronic hepatitis, liver impairment and drug toxici-
ty  may  substantially  reduce  the  number  of  possible
therapeutic options. 
Case  Description: we  here  describe  the  case  of  an
Hcv-HIv coinfected woman who had repeated severe
episodes of drug-related liver toxicity with indinavir,
saquinavir,  fosamprenavir,  and  darunavir,  with  mini-
mal further therapeutic options left in this class. Previ-
ous treatment-limiting side effects with efavirenz and
nevirapine also precluded use of non-nucleoside re-
verse transcriptase inhibitors. Introduction of an inte-
grase-inhibitor regimen based on raltegravir, tenofovir,
and  emtricitabine  allowed  a  prompt  achievement  of
undetectable viral load and a substantial rise of cd4
count to high levels, with no subsequent episodes of
hepatic toxicity, and no other side effects. 
Conclusions: given  the  relatively  common  prevalence
of Hcv-related chronic hepatitis among people with
HIv, raltegravir might represent an important alterna-
tive option for a substantial number of patients who
cannot be treated with protease inhibitors or nnRtI
because of drug-related hepatic toxicity.
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backgRound
Hcv-infected  patients  who  are  also  coinfected  with
HIv are at higher risk of progression of liver disease
compared with patients infected with Hcv alone [1].
In the case of chronic Hcv infection, some antiretro-
viral  drugs  with  potential  hepatotoxicity  should  be
avoided or be used with particular care. the risk of
hepatic toxicity is particularly high for nnRtIs, which
often cannot be prescribed safely because of a sub-
stantial risk of severe and sometimes fatal hepatic re-
actions [2, 3]. although less frequently, severe hepatic
reactions  may  also  be  observed  with  protease  in-
hibitors [4-7], and in such situations there may be lim-
ited therapeutic options left for an effective viral sup-
pression. Integrase inhibitors represent innovative and
promising drugs for patients who are intolerant or re-
sistant  to  other  classes  of  antiretroviral  drugs  [8-9],
and  are  increasingly  used  in  salvage  regimens,  with
favourable  immunological  and  virological  responses.
In the bEncHMRk studies, where Hcv prevalence
was about 10%, the occurrence of grade 3-4 liver en-
zyme  elevations  was  low  (3.5-4.3%),  suggesting  that
raltegravir may be characterised by a favourable hepat-
ic safety profile [10]. we here describe the case of an
Hcv-HIv coinfected woman with repeated episodes
of  severe  liver  toxicity  attributable  to  protease  in-
hibitors who was successfully switched to a regimen
based on raltegravir, tenofovir and emtricitabine.
casE dEscRIPtIon
our patient, currently 43 years of age, born and living
in Italy, was diagnosed with Hcv in 1995 (positive for
Hcv Igg antibodies, Hcv genotype 1a), at the age
of 28, during a serological screening. tests for Hbv
infection (Hbv surface antigen, Hbv surface and core
antibody) were negative. In 1996, a diagnosis of HIv
infection was made and the patient reported an history
of previous intravenous drug use. she was clinically
asymptomatic,  with  no  history  of  past  HIv-related
symptoms, and a cd4 cell count of 318/mm3 at that
time (cdc stage a2). a mild elevation of serum alt
concentrations (51 Iu/l, reference range, 1-36 Iu/l)
was present. before starting antiretroviral therapy, the
patient had a first cycle of interferon treatment, ad-
ministered  three  times  per  week  for  seven  months,
with no response to treatment. on March 1997 a com-
bination regimen based on zidovudine plus didanosine
was started, and on June 1998 this regimen was dis-
continued in order to introduce a PI-based HaaRt
represented by zidovudine (Zdv), lamivudine (3tc)
and indinavir. the treatment was effective in raising
cd4 count (to 597/mm3) and decreasing viral load to
undetectable levels within six months, but in septem-
ber 1998 indinavir had to be replaced by saquinavir
because of renal lithiasis, nausea, vomiting and actg
grade 3 hepatic toxicity (alt 248 u/l). treatment was
maintained for about two years until the end of 2000,
with limited adherence and development of resistance
mutations  to  both  reverse  transcriptase  (41l,  67n,
184v,  215y,  219E)  and  HIv  protease  (73s,  90M).
from  January  2001  to  July  2002  different  regimens
based  on  nnRtI  were  given,  but  compliance  re-
mained  low,  virological  response  was  limited  (viral
load  undetectable  in  2001,  then  rebounded  to  2270
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7. Ortu_Umbruchvorlage  12.02.10  11:14  Seite 81copies in 2002), and the patient developed side effects
that required interruption of nnRtI treatment (first
d4t+3tc+Efv, because of cns symptoms, and sub-
sequently d4t+ddI+ nevirapine, because of rash). In
october 2002, a simplified regimen based on abacavir
was  started  (d4t+ddI+abc).  In  april  2003,  during
treatment with this regimen, a genotypic resistance test
was performed (viral load at the moment of the test:
2350 copies/ml), that substantially confirmed the mu-
tation  pattern  observed  two  years  before  (Rt:  41l,
67l, 184v, 215y; PR: 73s, 90M). a liver biopsy was
performed in May 2005. the results showed a general
liver architecture altered by the presence of porto-por-
tal septa and periterminal fibrosis, with inflammatory
infiltration  of  portal  spaces,  piecemeal  peripheral
necrosis, and focal steatosis. a diagnosis of chronic
hepatitis with moderate activity was made.
In september 2005 the patient started a new anti-
retroviral regimen based on abacavir, lamivudine and
fosamprenavir/ritonavir. while the patient was on this
regimen, she had two cycles of treatment with PEg-
interferon alpha-2a plus ribavirine (800 mg per day) in
July 2006 (administered for three months) and decem-
ber 2006, respectively, with no response (Hcv-Rna
viral load in July 2007: 1,500,000 Iu/ml). at the end
of the second cycle the patient presented with asthe-
nia,  anorexia  and  hepatomegaly,  and  blood  test  re-
vealed the presence of transaminase levels >5xunl
(actg grade 3 toxicity). antiretroviral treatment was
discontinued,  with  regression  of  liver  toxicity  (alt
and ast levels of 108 and 87 u/l, respectively, in Jan-
uary 2008). the reduced transaminase levels allowed
the introduction of a new regimen based on tenofovir,
emtricitabine and darunavir/ritonavir in March 2008.
new blood tests in July 2008 revealed the presence of
severe liver toxicity (alt 515, ast 419, correspond-
ing to actg grade 4 toxicity). this regimen was dis-
continued, with a prompt reduction of transaminase
levels (alt 109, ast 76 in october 2008). In octo-
ber 2008, following a two-month period of treatment
discontinuation, raltegravir was introduced (with teno-
fovir and emtricitabine). at this point (baseline for ral-
tegravir  treatment)  the  patient  had  a  cd4  count  of
542  cells/mm3,  an  HIv-Rna  viral  load  of  16380
copies/ml (4.21 log10 /ml), and mildly increased alt
and ast levels (109 and 98 u/l, respectively). after
one month of treatment (november 2008) transami-
nase levels showed no increase (alt 96, ast 76). In
January 2009 cd4 cell count increased to 762/mm3
and  viral  load  had  became  undetectable  (<50
copies/ml, 1.69 log10). alt and ast levels were 146
and 128, respectively. In the following evaluation, in
april  2009,  HIv-Rna  remained  undetectable,  cd4
count  increased  to  927/mm3 and  liver  enzymes  re-
mained stable at relatively low levels (alt 83, ast
67).  such  data  were  substantially  confirmed  at  two
subsequent evaluations in July 2009 (cd4 926/mm3,
HIv-Rna <50 copies/ml, alt 130, ast 105) and in
september  2009  (cd4  956/mm3,  HIv-Rna  <50
copies/ml, alt 92, ast 114). during subsequent fol-
low up, the patient is maintaining good clinical condi-
tions and remains compliant with treatment.
dIscussIon
liver toxicity represents a frequent drug-related com-
plication in patients receiving antiretroviral treatment,
and may commonly lead to interruption of treatment
and /or hospital admission [11]. the risk of severe he-
patic  toxicity  under  antiretroviral  treatment  is  in-
creased in the presence of Hcv coinfection [6, 12,
13], and in such patients it is not always possible to as-
sess the individual role of antiretroviral treatment and
Hcv coinfection in such events. the clinical history
of our patient clearly indicated the presence of hepat-
ic intolerance to protease inhibitors, with episodes of
severe toxicity that promptly reversed following dis-
continuation  of  treatment.  such  episodes  occurred
during  treatment  with  different  protease  inhibitors,
such  as  indinavir,  saquinavir,  fosamprenavir,  and
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Fig. 1. HIv Rna viral load, alt/ast levels, cd4 cell count and antiretroviral treatment. alt: alanine aminotransferase;
ast: aspartate aminotransferase; tdf: tenofovir; ftc: emtricitabine; dRv/r: darunavir/ritonavir. 
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darunavir, leaving very limited therapeutic options in
this class. use of non-nucleoside reverse transcriptase
was also precluded because of previous side effects
with both efavirenz and nevirapine. 
In this patient use of raltegravir allowed to obtain
undetectable viral load and high cd4 levels, with no
subsequent flares of hepatic toxicity, and no other rel-
evant side effect. this favourable clinical course with a
regimen that introduced an integrase inhibitor main-
taining a nucleos(t)ide backbone add further support
to the hypothesis that previous episodes of liver toxic-
ity were attributable to protease inhibitors and not to
the nucleoside backbone concomitantly given to the
patient. some of the episodes occurred following anti-
Hcv  treatment,  and  interferon  or  ribavirine  might
also have played a facilitating role in the development
of toxicity.
there is as yet limited information on the use of
raltegravir in patients coinfected with Hcv, and fur-
ther studies should evaluate its safety and efficacy in
this particular population. Recent data by vispo et al.
suggest that, even if Hcv-coinfected patients receiv-
ing raltegravir may have an additional risk of liver toxi-
city compared to raltegravir-treated HIv monoinfect-
ed persons, this usually translates in mild liver enzyme
elevations only, with no cases of grade 3-4 liver toxici-
ty directly attributable to the drug [14]. given the rela-
tively common prevalence of Hcv coinfection among
people with HIv, raltegravir might represent an im-
portant alternative option for a substantial number of
patients  who  cannot  be  treated  with  protease  in-
hibitors or nnRtI because of hepatic intolerance.
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